Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Long-Term Investments (2021 - 2025)

Bolt Biotherapeutics' Long-Term Investments history spans 5 years, with the latest figure at $6.9 million for Q3 2025.

  • For Q3 2025, Long-Term Investments fell 77.43% year-over-year to $6.9 million; the TTM value through Sep 2025 reached $6.9 million, down 77.43%, while the annual FY2024 figure was $22.9 million, 13.38% down from the prior year.
  • Long-Term Investments for Q3 2025 was $6.9 million at Bolt Biotherapeutics, down from $13.7 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $85.3 million in Q4 2021 and bottomed at $6.9 million in Q3 2025.
  • The 5-year median for Long-Term Investments is $30.6 million (2024), against an average of $36.4 million.
  • The largest annual shift saw Long-Term Investments soared 49.89% in 2022 before it tumbled 77.43% in 2025.
  • A 5-year view of Long-Term Investments shows it stood at $85.3 million in 2021, then crashed by 71.95% to $23.9 million in 2022, then grew by 10.32% to $26.4 million in 2023, then decreased by 13.38% to $22.9 million in 2024, then plummeted by 69.82% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Long-Term Investments are $6.9 million (Q3 2025), $13.7 million (Q2 2025), and $19.1 million (Q1 2025).